What is William Blair’s Estimate for BRNS Q1 Earnings?

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Barinthus Biotherapeutics in a research note issued on Wednesday, May 7th. William Blair analyst A. Hsieh expects that the company will earn ($0.41) per share for the quarter. The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.44) EPS and Q4 2026 earnings at ($0.44) EPS.

Several other brokerages have also recently commented on BRNS. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday, March 21st. Alliance Global Partners reissued a “buy” rating on shares of Barinthus Biotherapeutics in a research note on Monday, March 24th.

Barinthus Biotherapeutics Price Performance

BRNS stock opened at $0.87 on Friday. The company has a 50 day moving average price of $0.89 and a 200 day moving average price of $1.02. The stock has a market capitalization of $34.97 million, a PE ratio of -0.58 and a beta of -0.80. Barinthus Biotherapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.44.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15).

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises about 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th biggest position. Gilead Sciences Inc. owned about 1.54% of Barinthus Biotherapeutics at the end of the most recent quarter. 25.20% of the stock is owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.